Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $131.4 million.

  • Catalyst Pharmaceuticals' Total Liabilities rose 1826.61% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $131.4 million, marking a year-over-year increase of 1826.61%. This contributed to the annual value of $123.8 million for FY2024, which is 5052.23% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Total Liabilities of $131.4 million as of Q3 2025, which was up 1826.61% from $115.9 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Total Liabilities registered a high of $131.4 million during Q3 2025, and its lowest value of $18.6 million during Q1 2021.
  • Its 5-year average for Total Liabilities is $71.3 million, with a median of $73.6 million in 2023.
  • Its Total Liabilities has fluctuated over the past 5 years, first decreased by 12.06% in 2021, then soared by 17500.28% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Total Liabilities (Quarter) stood at $31.0 million in 2021, then soared by 142.95% to $75.2 million in 2022, then rose by 9.34% to $82.2 million in 2023, then surged by 50.52% to $123.8 million in 2024, then grew by 6.12% to $131.4 million in 2025.
  • Its last three reported values are $131.4 million in Q3 2025, $115.9 million for Q2 2025, and $114.6 million during Q1 2025.